Moreover, as HDAC inhibitors restore RUNX3 expression and tumor-suppressive function in cancer cells [103,108,109], it has been suggested that under hypoxic conditions, compounds that rescue the epigenetic loss of RUNX3 expression and protein function could potentially be utilized for the prevention and treatment of various cancers. This evidence concerns the gene RUNX3 and cancer.